Skip to main content
. Author manuscript; available in PMC: 2018 Jan 3.
Published in final edited form as: Vaccine. 2016 Nov 23;35(1):164–169. doi: 10.1016/j.vaccine.2016.11.012

Table 2.

Clinician Knowledge about HPV and HPV Vaccine1

Clinician questions/responses,2 (T/F) Correct, % Incorrect or Unsure, % Missing, %
Most HPV infections resolve without medical intervention (T) 82.1 16.5 1.4
Treatment of cervical dysplasia/cancer permanently eliminates the causative infection (F) 91.4 7.9 0.7
Genital warts are caused by the same HPV types that cause cervical cancer (F) 60.4 38.9 0.7
Almost all cervical cancers are caused by HPV infection (T) 92.9 6.7 0.4
The ACIP, CDC, ACP, ACOG, AAFP, and AAP recommend the bivalent, quadrivalent, and nonavalent HPV vaccine for all females ages 11 to 26 years with permission to start at 9 to 10 years of age (T) 93.6 6.0 0.4
The ACIP, CDC, ACP, ACOG, AAFP, and AAP recommend the quadrivalent and nonavalent HPV vaccine for all males ages 11 to 21 years with permission to start at 9 to 10 years of age and for males at high risk or seeking immunity 22 to 26 years of age (T) 90.4 8.9 0.7
Females who have been diagnosed with HPV infection should not be given the HPV vaccine (F) 91.4 8.2 0.4
Males who have been diagnosed with HPV infection should not be given the HPV vaccine (F) 90.7 8.9 0.4
HPV causes vulvar, vaginal, and anal cancers in women (T) 91.8 7.8 0.4
HPV causes anal cancers in men (T) 95.4 4.2 0.4
HPV causes head and neck cancers (T) 81.8 17.8 0.4
1

N=280

2

Correct response is shown in True/False (T/F)

Abbreviations: AAFP, American Academy of Family Physicians; AAP, American Academy of Pediatrics; ACIP, Advisory Committee on Immunization Practices; ACOG, American Congress of Obstetricians and Gynecologists; ACP, American College of Physicians; CDC, Centers for Disease Control and Prevention; HPV, Human Papillomavirus